QRxPharma soars on pain drug deal

Shares in QRxPharma have jumped 10 per cent in early trade after it unveiled a partnership agreement with Iceland’s Actavis Group to launch its acute pain drug MoxDuo in to the $US2.5 billion a year US market.

Although the fine detail of the agreement is yet to be written, and depends entirely on the US Food and Drug Administration approving MoxDuo for the market in late June, QRxPharma has received a non-refundable $6 million upfront fee as downpayment by Actavis. Sydney Morning Herald – Read more…